Stem Cell Extracellular Vesicles as Anti-SARS-CoV-2 Immunomodulatory Therapeutics: A Systematic Review of Clinical and Preclinical Studies
Open Access
- 23 February 2024
- journal article
- review article
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 20 (4) , 900-930
Abstract
Background: COVID-19 rapidly escalated into a worldwide pandemic with elevated infectivity even from asymptomatic patients. Complications can lead to severe pneumonia and acute respiratory distress syndrome (ARDS), which are the main contributors to death. Because of their regenerative and immunomodulatory capacities, stem cells and their derived extracellular vesicles (EVs) are perceived as promising therapies against severe pulmonary conditions, including those associated with COVID-19. Herein, we evaluate the safety and efficacy of stem cell EVs in treating COVID-19 and complicating pneumonia, acute lung injury, and ARDS. We also cover relevant preclinical studies to recapitulate the current progress in stem cell EV-based therapy. Methods: Using PubMed, Cochrane Central Register of Controlled Trials, Scopus, and Web of Science, we searched for all English-language published studies (2000–2023) that used stem cell EVs as a therapy for COVID-19, ARDS, or pneumonia. The risk of bias (ROB) was assessed for all studies. Results: Forty-eight studies met our inclusion criteria. Various-sized EVs derived from different types of stem cells were reported as a potentially safe and effective therapy to attenuate the cytokine storm induced by COVID-19. EVs alleviated inflammation and regenerated the alveolar epithelium by decreasing apoptosis, proinflammatory cytokines, neutrophil infiltration, and M2 macrophage polarization. They also prevented fibrin production and promoted the production of anti-inflammatory cytokines and endothelial cell junction proteins. Conclusion: Similar to their parental cells, stem cell EVs mediate lung tissue regeneration by targeting multiple pathways and thus hold promise in promoting the recovery of COVID-19 patients and improving the survival rate of severely affected patients. GraphicalKeywords
Funding Information
- Science and Technology Development Center, Ministry of Education (46721)
- Science, Technology and development fund STDF in cooperation with Egyptian Knowledge bank (000)
- Sawaris Scholarship for Stem Cell Research (000)
- Zewail City of Science & Technology
This publication has 122 references indexed in Scilit:
- Using Qualitative Evidence in Decision Making for Health and Social Interventions: An Approach to Assess Confidence in Findings from Qualitative Evidence Syntheses (GRADE-CERQual)PLOS Medicine, 2015
- Therapeutic Effects of Human Mesenchymal Stem Cell–derived Microvesicles in Severe Pneumonia in MiceAmerican Journal of Respiratory and Critical Care Medicine, 2015
- Exosomes as Potential Alternatives to Stem Cell Therapy in Mediating Cardiac RegenerationCirculation Research, 2015
- Regulators of pluripotency and their implications in regenerative medicineStem Cells and Cloning: Advances and Applications, 2015
- Differential fates of biomolecules delivered to target cells via extracellular vesiclesProceedings of the National Academy of Sciences, 2015
- Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paperJournal of Extracellular Vesicles, 2015
- SYRCLE’s risk of bias tool for animal studiesBMC Medical Research Methodology, 2014
- Human Mesenchymal Stem Cell Microvesicles for Treatment of Escherichia coli Endotoxin-Induced Acute Lung Injury in MiceStem Cells, 2014
- Acute Respiratory Distress SyndromeJAMA, 2012
- Surgically relevant aspects of stem cell paracrine effectsSurgery, 2008